Join the 'Lubiprostone' group to help and get support from people like you.
Posted 8 Aug 2014 by Drugs.com
FRIDAY, Aug. 8, 2014 – Newly released guidelines for the treatment of irritable bowel syndrome and a type of constipation known as chronic idiopathic constipation reveal a number of proven treatments for these two common conditions. "There's a greater variety of approaches which reflect a greater understanding of the disorders," said guidelines co-author Dr. Eamonn Quigley, chief of the division of gastroenterology and hepatology at Houston Methodist Hospital. "We now have a better opportunity to improve the lives of our patients," Quigley said. The guidelines are published in the August issue of the American Journal of Gastroenterology. An estimated 5 percent to 15 percent of the world's population has irritable bowel syndrome, a condition that can cause symptoms such as abdominal pain, diarrhea or constipation, cramping and bloating, and gas. It can affect people at any age but is ... Read more
Related support groups: Irritable Bowel Syndrome, Linzess, MiraLax, Dulcolax, Constipation - Chronic, Lactulose, Amitiza, Polyethylene Glycol 3350, Xifaxan, Metamucil, Bisacodyl, Rifaximin, Psyllium, Linaclotide, Duphalac, ClearLax, Konsyl, Dulcolax Laxative, GlycoLax, Kristalose
Posted 23 Apr 2013 by Drugs.com
BETHESDA, Md. & DEERFIELD, Ill.--(BUSINESS WIRE)--Apr. 23, 2013-- Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Sucampo’s supplemental new drug application (sNDA) for Amitiza (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain. The effectiveness of Amitiza in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. This is the third indication for Amitiza, which is also approved in the U.S. for the treatment of chronic idiopathic constipation (CIC) in adults (24 mcg twice daily) and irritable bowel syndrome with constipation (IBS-C) in adult women (8 mcg twice daily). There ... Read more